Restless Legs Syndrome keeps over five million Americans up at night.
Soon, they might be able to chew some cannabinoid gum before bed to get a good night’s sleep.
Innovative biotechnology company AXIM® Biotechnologies, Inc. announced they’ll soon start Phase II clinical trials on its newest cannabidiol (CBD)-based chewing gum.
This latest move from AXIM® Biotech comes on the heels of its announcement earlier this summer that the company filed a patent for a chewing gum designed to treat opioid addiction.
Also known as Willis-Ekbom Disorder, Restless Legs Syndrome is a neurological sensorimotor condition characterized by an irresistible urge to move the legs. RLS often leads to significant sleep problems that adversely affect mood, stress levels, immune function, and general health.
There is currently no accepted cure for the condition, treatment efforts typically focus on managing its associated symptoms with drugs, massage, hot baths, physical activity, and alternating hot and